



**BRITISH**

**MEDICAL JOURNAL**



## **British Medical Journal Volume 1, No 2., 2021**

**Internet address:** <http://ejournals.id/index.php/bmj>

**E-mail:** [info@ejournals.id](mailto:info@ejournals.id)

Published by British Medical Journal

Issued Bimonthly

3 knoll drive. London. N14 5LU United Kingdom

+44 7542 987055

Chief Editor

**Dr. Fiona Egea**

*Requirements for the authors.*

*The manuscript authors must provide reliable results of the work done, as well as an objective judgment on the significance of the study. The data underlying the work should be presented accurately, without errors. The work should contain enough details and bibliographic references for possible reproduction. False or knowingly erroneous statements are perceived as unethical behavior and unacceptable.*

*Authors should make sure that the original work is submitted and, if other authors' works or claims are used, provide appropriate bibliographic references or citations. Plagiarism can exist in many forms - from representing someone else's work as copyright to copying or paraphrasing significant parts of another's work without attribution, as well as claiming one's rights to the results of another's research. Plagiarism in all forms constitutes unethical acts and is unacceptable. Responsibility for plagiarism is entirely on the shoulders of the authors. Significant errors in published works. If the author detects significant errors or inaccuracies in the publication, the author must inform the editor of the journal or the publisher about this and interact with them in order to remove the publication as soon as possible or correct errors. If the editor or publisher has received information from a third party that the publication contains significant errors, the author must withdraw the work or correct the errors as soon as possible.*

**OPEN ACCESS**

Copyright © 2021 by British Medical Journal

**British Medical Journal** Volume-1, No 2

## Adherence to anti-retroviral therapy in children

Tuychiev L.N., Sadikov X-M.A., Khudaykulova G.K., Muminova M.T.,  
Rakhmatullaeva Sh.B.  
Tashkent Medical Academy

**Abstract.** Adherence to antiretroviral therapy is key to success and survival among people living with HIV. Despite this, the low level of adherence is one of the main problems in the provision of medical care for HIV-infected people in many countries due to the high level of formation of resistant strains of the virus and, consequently, the ineffectiveness of ART. Data from a systematic review and meta-analysis conducted in Ethiopia demonstrate different levels of adherence to ART in children with HIV infection in different cities of the same state [7]. Similar results were obtained in a study conducted in Nigeria [24]. Chinese scientists, after conducting a meta-analysis and a systematic review, also concluded that adherence rates are highly heterogeneous among different age groups of people [11]. The Indian scientists K. Mehta, M.L. Ekstrand, E. Heilen, GN Sanjiva and A. Sheth [14], conducting a study in the southern regions of India. The variety of research results obtained in different countries of the world prompted us to study the level of adherence to antiretroviral therapy in HIV-infected children, which was the purpose of this work.

**Keywords:** HIV, antiretroviral therapy, adherence, children.

**Material and methods.** The study was conducted from 2018 to 2021. on the basis of the HIV infection department of the Research Institute of Virology of the Ministry of Health of the Republic of Uzbekistan, as well as on the basis of a specialized clinic at the Republican Center for the Fight against AIDS and the city center for the fight against AIDS in Tashkent. 112 children diagnosed with HIV infection at the age from 0 to 18 years were under observation.

The diagnosis of HIV infection was established on the basis of the order of the Ministry of Health of the Republic of Uzbekistan No. 277 dated April 30, 2018 “On the implementation of national clinical protocols for HIV infection”.

The clinical stage of HIV infection was established in accordance with the classification of HIV infection in children in accordance with the current orders of the Ministry of Health of the Republic of Uzbekistan.

When assessing the level of adherence, we used the WHO criteria modified by O.I. Fedyaeva. (2014) (table 1)

Key criteria for adherence to antiretroviral therapy

No	Commitment criteria	High commitment	Moderate commitment	Low adherence
1	Percentage of taking physician-prescribed doses	95% or more	80 +90%	79% or less
2	The number of		3-10 doses	More than 10


	single doses missed per month when taken 2 times a day	Less than 3 or 1 day	or 1.5 to 5 days	doses or 5.5 or more days
3	The daily intake of drugs per month is:	29 and more	25-28.5 days	24.5 days or less
4	Reception clearly at the set time with fluctuations	Up to 30 minutes	Within 2 hours	More than 2 hours
5	Taking medications in accordance with the specified dietary regimen	Constantly	Sometimes not carried out	More often not carried out
6.	Self-passes for no good reason	Absent	Single	Frequent
7.	The psychological attitude of commitment	There is	Does not take an active position, but agree with the doctor	No

The data obtained during the study were subjected to statistical processing on a Pentium-IV personal computer using the Microsoft Office Excel-2012 software package, including the use of built-in statistical processing functions.

**Results and discussion.** We have determined the levels of adherence in children included in our study. The results are shown in diagram 1.

**Diagram 1**

**Assessment of the state of adherence to ART in the examined children**




According to our analysis, among the children we surveyed, the distribution of adherence to ARVT was approximately the same. Children whose adherence to ARV drugs was at a high level - 37.5% (42 children), a moderate level of adherence -

28.6% (32 children) and a low level of adherence - 33.9% (38 children) (  $p>0.05$ ). For further analysis, we examined the state of adherence to ART in different age groups (Diagram 2.).

**Diagram 2**


**The state of adherence to ART in different age groups**



The analysis showed that in the group of children under 3 years old, in most cases, there was a high level of adherence (58.3%), which is apparently explained by the fact that young children are in the care of parents / close relatives / guardians.

A quarter of children (25%) had a moderate level of adherence. These were mainly children 2.5-3 years old, infected perinatally. Although they were in the care of relatives / parents / guardians, nevertheless, in these cases we noted the so-called “therapeutic fatigue” in the caregivers, which explains the missed medication. A low level of adherence was registered in 16.7% of children. When analyzing the possible reasons, it was revealed that these were children from disadvantaged families, where their parents suffered from various kinds of addictions (alcohol, drug), which influenced adherence to the treatment regimen. The next stage of our work was to study the age structure at different levels of adherence to ART. The results are shown in diagram 3.

### Age structure at different levels of adherence to ART



The analysis showed that among children with high and moderate levels of adherence, children aged 3 to 7 years predominated (50% and 62.5%, respectively).

We explain this, first of all, by the peculiarities of our sample, namely, the predominance of this age category among the surveyed children.

Among children with a high level of adherence, a smaller proportion (26.2% were children 7-14 years old). The lowest specific gravity was found among young children - up to 3 years old (16.7%) and adolescents 14-18 years old (7.1%).

Among children with a moderate level of adherence, the above age groups (except for the category from 3 to 7 years old) had an almost equal distribution within 10-15%).

Interesting data were obtained when analyzing the age structure of children with a low level of adherence. The smallest proportion was observed in children under 3 years of age (only 5.3%), which is explained, as we described above, by the care of the caregivers. Children of other age groups (3-7 years old, 7-14 years old and 14-18 years old) were registered with almost equal frequency (within 30%). Thus, among HIV-infected children, there was an approximately equal distribution of different levels of adherence (one third each). The worst adherence rates were observed in the 7-14 and 14-18 age groups. A similar trend is shown in a number of foreign studies [2, 12, 17, 19, 21]. Adolescents and young people tend to have poorer adherence to treatment for many chronic conditions [9, 10, 15, 18]. In the case of HIV infection, the level of adherence is influenced by stigma [3, 4, 5, 8]. In addition, adolescence is characterized as a time of significant physiological and psychological growth and development [1, 2], an increased desire for independence from parents [6] and an increased risk [25], adding another level of difficulty in maintaining adherence to ART. Adolescents are also characterized by a lack of financial independence, a tendency to pressure from peers, and a lack of problem-solving skills [13, 16, 20, 22,

23]. All these factors may explain the relatively high level of adherence to ART in this category of patients, in contrast to young children, for which adherence is largely the responsibility of adults.

**Conclusion:** Based on the studies carried out, it can be concluded that as the child grows up (over 3 years old), the state of adherence tends to deteriorate. To correct the situation, a detailed analysis of the reasons affecting the state of adherence is necessary, and the development of measures to level or weaken them.

**References:**

1. Abubakar A, Van de Vijver FJ, Fischer R, et al. 'Everyone has a secret they keep close to their hearts': challenges faced by adolescents living with HIV infection at the Kenyan coast. *BMC Public Health*. 2016;16:197.
2. Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. *J Int AIDS Soc*. 2015;18:20049
3. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. *Psychosomatics*. 2004;45(5):394–402.
4. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. *J Acquir Immune Defic Syndr*. 2002;31(Suppl 3):S123–S127.
5. Ammassari AA, Starace F, Aloisi MS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. *Neurology*. 2003;61(5):723–724.
6. Choudhury S, Blakemore SJ, Charman T. Social cognitive development during adolescence. *Soc Cognit Affect Neurosci*. 2006;1(3):165–174.
7. Endalamaw, A., Tezera, N., Eshetie, S. et al. Adherence to Highly Active Antiretroviral Therapy Among Children in Ethiopia: A Systematic Review and Meta-analysis. *AIDS Behav* 22, 2513–2523 (2018). <https://doi.org/10.1007/s10461-018-2152-z>.
8. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. *Patient Educ Couns*. 2002;46(2):93–108.
9. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2008;2:Cd000011
10. Haynes RB, Sackett DL, Taylor DW. How to detect and manage low patient compliance in chronic illness. *Geriatrics*. 1980;35(1):91.
11. Huan Z, Fuzhi W, Lu L, Min Z, Xingzhi C, Shiyang J. Comparisons of Adherence to Antiretroviral Therapy in a High-Risk Population in China: A Systematic Review and Meta-Analysis. *PLoSOne*. 2016;11(1):e0146659. Published 2016 Jan 12. doi:10.1371/journal.pone.0146659.
12. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, et al. High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care. *AIDS*. 2014;28(4):559–568.

13. Laughton B, Cornell M, Boivin M, Van Rie A. Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. *J Int AIDS Soc.* 2013;16:18603.
14. Mehta K, Ekstrand ML, Heylen E, Sanjeeva GN, Shet A. Adherence to Antiretroviral Therapy Among Children Living with HIV in South India. *AIDS Behav.* 2016 May;20(5):1076-83. doi: 10.1007/s10461-015-1207-7. PMID: 26443264; PMCID: PMC5472452.
15. Morrissey EC, Durand H, Nieuwlaat R, et al. Effectiveness and content analysis of interventions to enhance medication adherence in hypertension: a systematic review and meta-analysis protocol. *Syst Rev.* 2016;5:96.
16. Mutumba M, Musiime V, Lepkewski JM, et al. Examining the relationship between psychological distress and adherence to anti-retroviral therapy among Ugandan adolescents living with HIV. *AIDS Care.* 2016;28(7):807–815.
17. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. *Current Opinion in HIV and AIDS.* 2010;5(1):70–77
18. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev.* 2014;11:Cd000011.
19. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med.* 2000;133(1):21–30.
20. Petersen I, Bhana A, Myeza N, et al. Psychosocial challenges and protective influences for socio-emotional coping of HIV+ adolescents in South Africa: a qualitative investigation. *AIDS Care.* 2010;22(8):970–978.
21. Salou M, Dagnra AY, Butel C, et al. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo. *J Int AIDS Soc.* 2016;19(1):20683.
22. Smith R, Chernoff M, Williams PL, et al. Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. *Pediatr Infect Dis J.* 2012;31(6):592–598.
23. Tanney MR, Naar-King S, MacDonnel K. Depression and stigma in high-risk youth living with HIV: a multi-site study. *J Pediatr Health Care.* 2012;26(4):300–305.
24. Ugwu R, Eneh A. Factors influencing adherence to paediatric antiretroviral therapy in Portharcourt, South- South Nigeria. *Pan Afr Med J.* 2013 Sep 29;16:30. doi: 10.11604/pamj.2013.16.30.1877. PMID: 24570791; PMCID: PMC3932123..
25. Willoughby T, Good M, Adachi PJC, Hamza C, Tavernier R. Examining the link between adolescent brain development and risk taking from a social-developmental perspective. *Brain Cogn.* 2013;83:315–323.